TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 in the PRE-I-SPY Phase 2a clinical trial platform. The study plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy, beginning in the first half of 2026 and led by Dr. Paula Pohlmann of MD Anderson Cancer Center.
The trial will assess the biological and clinical activity of TTX-MC138 in the minimal residual disease setting, where recurrence risk is high and therapeutic options are limited. This reflects growing interest in precision treatments targeting micrometastatic disease, a critical frontier in oncology where traditional therapies often fall short. TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers, with TTX-MC138 focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.
For business and technology leaders in healthcare and biotechnology, this collaboration represents a strategic move toward addressing one of oncology's most persistent challenges: preventing cancer recurrence after initial treatment. The partnership between a clinical stage biotech company and a healthcare collaborative specializing in adaptive trial platforms could accelerate the development pathway for precision oncology treatments. The trial's focus on minimal residual disease—a state where cancer cells remain in the body after treatment but are undetectable by conventional imaging—targets a critical window where intervention could prevent full-blown metastatic recurrence.
The implications for the healthcare industry are substantial, as successful demonstration of TTX-MC138's efficacy in this setting could establish a new treatment paradigm for colorectal cancer and potentially other solid tumors. This approach aligns with the broader trend toward personalized medicine and liquid biopsy technologies, where circulating tumor DNA (ctDNA) detection enables earlier intervention. For investors and industry observers, the collaboration demonstrates how adaptive trial platforms like PRE-I-SPY can streamline drug development by evaluating multiple therapeutic candidates simultaneously against shared control groups.
TransCode maintains a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells, positioning the company at the intersection of RNA therapeutics and immuno-oncology. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. The full press release about this collaboration can be viewed at https://ibn.fm/iX3ak.
This development comes as the oncology field increasingly recognizes that metastatic recurrence often originates from minimal residual disease that survives initial treatment. By targeting microRNA-10b, a driver of metastasis across multiple cancer types, TTX-MC138 could potentially address a fundamental mechanism of cancer spread rather than just treating established tumors. The collaboration's timing in 2026 allows for thorough preclinical work and regulatory preparation, suggesting both companies are taking a measured approach to this high-stakes clinical evaluation.
